CR20190361A - Dendrímeros terapéuticos - Google Patents

Dendrímeros terapéuticos

Info

Publication number
CR20190361A
CR20190361A CR20190361A CR20190361A CR20190361A CR 20190361 A CR20190361 A CR 20190361A CR 20190361 A CR20190361 A CR 20190361A CR 20190361 A CR20190361 A CR 20190361A CR 20190361 A CR20190361 A CR 20190361A
Authority
CR
Costa Rica
Prior art keywords
dendrimers
therapeutic
formula
disclosed
dendrimer
Prior art date
Application number
CR20190361A
Other languages
English (en)
Inventor
Iain Grant
Edward John Hennessy
Michael Giannis
William Mccoull
Marianne Bernice Ashford
David Owen
John Paul Secrist
Brian Kelly
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20190361A publication Critical patent/CR20190361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan dendrímeros de fórmula (I) y sales farmacéuticamente aceptables de los mismos. También se divulgan composiciones farmacéuticas que comprenden el dendrímero de fórmula (I) y métodos para usar los mismos para el tratamiento del cáncer.Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
CR20190361A 2017-02-22 2018-02-22 Dendrímeros terapéuticos CR20190361A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US201762591823P 2017-11-29 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (1)

Publication Number Publication Date
CR20190361A true CR20190361A (es) 2019-09-24

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190361A CR20190361A (es) 2017-02-22 2018-02-22 Dendrímeros terapéuticos

Country Status (23)

Country Link
US (4) US10314920B2 (es)
EP (1) EP3585441A1 (es)
JP (1) JP7074761B2 (es)
KR (2) KR20230093346A (es)
CN (2) CN117582521A (es)
AU (1) AU2018223149B2 (es)
BR (1) BR112019016409A2 (es)
CA (1) CA3053069A1 (es)
CL (1) CL2019002240A1 (es)
CO (1) CO2019009722A2 (es)
CR (1) CR20190361A (es)
DO (1) DOP2019000204A (es)
EC (1) ECSP19056271A (es)
IL (1) IL268648B (es)
JO (1) JOP20190191A1 (es)
MX (1) MX2019009442A (es)
NI (1) NI201900088A (es)
PE (1) PE20191660A1 (es)
PH (1) PH12019501896A1 (es)
SG (1) SG11201907334QA (es)
TW (1) TWI773730B (es)
UA (1) UA125655C2 (es)
WO (1) WO2018154004A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物
EP3883934A4 (en) * 2018-11-20 2023-01-11 Starpharma Pty Limited THERAPEUTIC DENDRIMETER
CA3152111A1 (en) * 2019-09-26 2021-04-01 David James Owen Therapeutic dendrimer
WO2021113651A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
IL297531A (en) 2020-04-24 2022-12-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods for treating severe acute respiratory distress syndrome
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
WO2022042583A1 (zh) 2020-08-25 2022-03-03 上海森辉医药有限公司 载药的大分子及其制备方法
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
ES2625109T3 (es) * 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
JP5989294B2 (ja) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
EP2052011B1 (en) * 2006-08-11 2020-11-04 Starpharma Pty Limited Targeted polylysine dendrimer therapeutic agent
CN101535280B (zh) 2006-11-15 2012-06-27 健泰科生物技术公司 芳基磺酰胺化合物
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
CN106008322B (zh) 2008-12-05 2018-09-04 Abbvie 公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG175253A1 (en) 2009-05-26 2011-11-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
DK2729179T3 (da) * 2011-06-06 2020-12-21 Starpharma Pty Ltd Makromolekyler
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
EP3152248B1 (en) * 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物

Also Published As

Publication number Publication date
US20200069810A1 (en) 2020-03-05
AU2018223149A1 (en) 2019-10-03
EP3585441A1 (en) 2020-01-01
MX2019009442A (es) 2019-10-09
US10314920B2 (en) 2019-06-11
CN110312531A (zh) 2019-10-08
CN117582521A (zh) 2024-02-23
DOP2019000204A (es) 2019-08-30
JOP20190191A1 (ar) 2019-08-08
SG11201907334QA (en) 2019-09-27
JP2020508985A (ja) 2020-03-26
US11717574B2 (en) 2023-08-08
IL268648A (en) 2019-10-31
IL268648B (en) 2022-04-01
US20240115716A1 (en) 2024-04-11
NI201900088A (es) 2020-03-18
WO2018154004A9 (en) 2018-12-27
US10888624B2 (en) 2021-01-12
PH12019501896A1 (en) 2019-10-21
TW201841659A (zh) 2018-12-01
CA3053069A1 (en) 2018-08-30
CL2019002240A1 (es) 2019-11-29
BR112019016409A2 (pt) 2020-04-07
PE20191660A1 (es) 2019-11-11
US20210060172A1 (en) 2021-03-04
CO2019009722A2 (es) 2019-09-18
TWI773730B (zh) 2022-08-11
WO2018154004A1 (en) 2018-08-30
JP7074761B2 (ja) 2022-05-24
UA125655C2 (uk) 2022-05-11
KR20230093346A (ko) 2023-06-27
US20180264127A1 (en) 2018-09-20
KR20190112330A (ko) 2019-10-04
KR102544033B1 (ko) 2023-06-14
ECSP19056271A (es) 2019-08-30
AU2018223149B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CO2019009722A2 (es) Dendrímeros terapéuticos
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
UY37205A (es) Inhibidores de bromodominios
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
AR111063A1 (es) Dendrímeros terapéuticos
EA201991924A1 (ru) Терапевтические дендримеры
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1